The Europe Gabapentin Market would witness market growth of 4.0% CAGR during the forecast period (2022-2028).
A persistent brain disorder that is not contagious. It is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the body or the entire body. Approximately, 4-10 per 1000 people are thought to be affected by active epilepsy, which is defined as having ongoing seizures or requiring treatment at any given moment in the general population. Each year, epilepsy is thought to affect 5 million people. According to estimates, epilepsy affects 49 of every 100,000 people in high-income nations.
This number can reach 139 per 100,000 in underdeveloped nations. This is probably caused by the increased risk of endemic diseases like neurocysticercosis or malaria, the increased frequency of birth-related injuries and injuries from motor vehicle accidents, as well as variations in the medical facilities, the provision of preventive health programs, and access to care. People with epilepsy comprise over 80% of the population in underdeveloped nations. As a result, epilepsy is one of the problems that are being treated with the use of gabapentin.
Sleep disorders are increasing in the region. Germany had a 4% prevalence of severe insomnia, lower than the 6-22% in other European nations. Most individuals have persistent symptoms, with many having significant sleep issues for over a year. Severe insomniacs have higher rates of visits to family doctors, prescription drug use, diagnostic tests, and hospitalization. As a result, many regional governments have increased their healthcare expenditures to lessen the burden of health issues like insomnia and chronic pain. Hence, the requirement for drugs to treat sleep disorders, chronic pain, and other problems are increasing the demand for gabapentin, which is advancing the market's growth.
The Germany market dominated the Europe Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $168.8 million by 2028. The UK market is anticipated to grow at a CAGR of 3.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 4.8% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
By Application
By Dosage Form
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 